Logic Biosciences

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering a nuclease-free approach to genome editing. The company's proprietary GeneRide platform utilizes homologous recombination to insert corrective genes into the genome without the need for exogenous nucleases or promoters, potentially offering a safer and more durable treatment for pediatric patients with rare genetic diseases. Additionally, their sAAVy platform is designed to develop optimized adeno-associated virus (AAV) capsids for improved delivery. In 2022, the company was acquired by Alexion, AstraZeneca Rare Disease, to bolster their genomic medicine capabilities and advance treatments for rare metabolic disorders.